Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of CRISPR-edited allogeneic anti-CLL-1 CAR-T cells for relapsed or refractory acute myeloid leukemia; the study status is terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy (anti-CLL-1 CAR-T cells)

Snippet

Sponsor: Caribou Biosciences, Inc. | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Status: TERMINATED